Key enzyme identified as potential target for cancer immunotherapy

Key enzyme identified as potential target for cancer immunotherapy

Scientists from A*STAR Genome Institute of Singapore (A*STAR GIS) have uncovered that a key enzyme—P4HA1 prolyl hydroxylase, is strongly induced in CD8+ T cells in solid cancer, the primary immune cells involved in combating cancer. P4HA1 causes disruptions in energy production within the cells, which leads to weaker immune cells that are less able to fight cancer and form long-lasting anti-cancer immunity, highlighting P4HA1 as a promising target for treating solid tumors.

​Medical Xpress – latest medical and health news stories

Read More


Discover more from Nurse Unity Chats

Subscribe to get the latest posts sent to your email.

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *